RCS - Oncimmune Hldgs PLC - Queen’s Award for Enterprise in Innovation 2022

Oncimmune HoldingsAnnouncement

21/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220421:nRSU8079Ia&default-theme=true

RNS Number : 8079I  Oncimmune Holdings PLC  21 April 2022

21 April 2022

 

RNS Reach

 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Oncimmune receives Queen's Award for Enterprise in Innovation 2022

 

Company's leading position in autoantibody-enabled immunodiagnostics
recognised for outstanding achievement in innovation with the UK's highest
official award for British business

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, today announces that it has been awarded the Queen's Award for
Enterprise 2022 in the innovation category, endorsing Oncimmune as a leading
developer of applied immunodiagnostics for the early detection of disease,
drug discovery and development.

 

With over 10 years as a leader in autoantibody-enabled immunodiagnostics,
Oncimmune is the leading global immunodiagnostics developer, primarily focused
on the fields of immuno-oncology, autoimmune disease and infectious diseases.
As a specialist immunology testing business, the Company has a diversified and
growing revenue stream from its discovery and development service-based
platform, delivering actionable insights into therapies to its pharmaceutical
and biotech partners, as well as a portfolio of diagnostic products to detect
early-stage cancer.

 

The Queen's Award for Enterprise 2022 acknowledges the innovation behind
Oncimmune's immunodiagnostic and discovery technology.  This started with
EarlyCDT, a blood test which can help identify cancer on average four years
earlier than current standard clinical diagnosis, and continues today through
Oncimmune's ImmunoINSIGHTS platform, which enables life science organisations
to optimise drug development and delivery, leading to more effective targeting
as well as safer treatments for patients.

 

The ImmunoINSIGHTS core immune-profiling technology is underpinned by a
library of over 8,800 immunogenic proteins, one of the largest of its kind,
which helps to identify clinical trial participants and patients in clinically
relevant subgroups, enabling the development of targeted, more effective
treatments with a lower risk of adverse events.

 

Regarded as the highest official UK award for British business and now in its
56(th) year, the Queen's Award for Enterprise is an annual award which
endorses outstanding achievement in innovation. Oncimmune is one of 226
organisations nationally to be recognised with a prestigious Queen's Award for
Enterprise 2022, which is awarded to products or services that have been
available on the market and can demonstrate outstanding innovation and
commercial success for at least two years.

 

The award will be formally presented to Dr Adam M Hill, Chief Executive
Officer (CEO), of Oncimmune, by His Royal Highness The Prince of Wales on 12
July 2022.

 

Dr Adam M Hill, CEO of Oncimmune said: "Oncimmune has established a
world-leading position in autoantibody-enabled immunodiagnostics, and we are
honoured to have our truly innovative approach recognised by the prestigious
Queen's Award for Enterprise 2022. Since our inception, the mission for
Oncimmune has been to use our extensive understanding of the immune system to
enable us to harness its sophisticated response to disease in order to detect
cancer earlier and to support the development of better therapies. We are
delighted to be recognised for the progress we have achieved in oncology,
other auto-immune and infectious diseases. I would like to thank all our
employees for their continued hard work and dedication in helping us to
achieve this vision and we look forward to what the future holds for Oncimmune
and its technology."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research center in Dortmund, Germany. The business platform enables
life science organisations to optimise drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDSIBDDGDG